Call us 24/7

The Targeted Agent and Profiling Utilization Registration (TAPUR) study


The TAPUR study is a clinical trial that aims to improve our understanding of how commercially available anti-cancer drugs perform on a broader range of cancers, by matching the drugs to tumors with specific genomic mutations that the drugs are designed to target.


Accepting new patients

Primary Study Objective(s)

  • To describe the anti-tumor activity and toxicity of commercially available, targeted anti-cancer drugs used for treatment of participants with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma with a genomic variant known to be a drug target or to predict sensitivity to a drug.
  • To record the treatment-related adverse events experienced by participants.
  • To create a prospective database of patient outcomes following treatment of participants with advanced solid tumors, multiple myeloma or B cell non-Hodgkin lymphoma that harbors a genomic variant known to be a target of an approved targeted anti-cancer drugs or to predict sensitivity to a drug with a commercially available targeted agent provided by the study.
  • To catalogue the commercially available tumor genomic tests used by clinical oncologists in the usual care of patients with advanced cancer.
  • To determine the concordance of the treatment plan proposed by the treating oncologist with that recommended by the Molecular Tumor Board in applicable situations.

Core eligibility

Note: This is only a partial list of eligibility criteria.

Generally speaking, qualifying participants must:

  • Be 18 or older
  • Not be pregnant or planning to become pregnant during the trial timeline
  • Not be bed-ridden
  • Have been diagnosed with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma
  • Have exhausted available standard treatment options
  • Have had a genomic or molecular test performed on their tumor
  • Have genomic test results that reveal their tumor has a mutation that may be targeted with a drug included in the trial and not approved for that cancer type
Learn more about your cancer

Accepting new patients


Learn more at


Principal Investigator(s)

Pamela Crilley
Eugene Ahn
Ashish Sangal